Brain and Central Nervous System TumorsPhase 3CATNONNCT00626990
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
A Phase 3 study testing temozolomide, DNA methylation analysis and laboratory biomarker analysis in people with Brain and Central Nervous System Tumors, run by European Organisation for Research and Treatment of Cancer - EORTC at 132 sites in 12 countries.
Trial summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- Brain and Central Nervous System Tumors
- What is being tested?
- temozolomide, DNA methylation analysis and laboratory biomarker analysis
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 751 participants
- Where
- 132 sitesin 12 countries
- Study dates
- Dec 2007to Dec 2029
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed diagnosis of 1 of the following:
- Anaplastic oligodendroglioma
- Anaplastic oligoastrocytoma
- Anaplastic astrocytoma
- Newly diagnosed disease
- Prior surgery for a low grade tumor is allowed, provided histological confirmation of an anaplastic tumor is present at the time of progression
- Absence of combined 1p/19q loss
- Tumor material available for central 1p/19q assessment, central O6-methylguanine-DNA methyltransferase promoter methylation status assessment, isocitrate dehydrogenase mutation analysis, and central pathology review
- Patients must be on a stable or decreasing dose of steroids for at least two weeks prior to randomization
PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9 cells/L
- Platelet count ≥ 100 x 10^9 cells/L
- Bilirubin < 1.5 x upper limit of normal (ULN)
- Alkaline phosphatase < 2.5 x ULN
- Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) < 2.5 x ULN
- Serum creatinine < 1.5 x ULN
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No known HIV infection or chronic hepatitis B or hepatitis C infection
- No other serious medical condition that would interfere with follow-up
- No medical condition that could interfere with oral medication intake (e.g., frequent vomiting or partial bowel obstruction)
- No other prior malignancies except for any malignancy which was treated with curative intent more than 5 years prior to registration and adequately controlled limited basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix
- No prior or concurrent malignancies at other sites except for surgically cured carcinoma in situ of the cervix or nonmelanoma skin cancer
- No psychological, familial, sociological, or geographical condition that would potentially hamper compliance with the study protocol and follow-up schedule
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior chemotherapy, including carmustine-containing wafers (Gliadel®)
- No prior radiotherapy to the brain
- No concurrent growth factors unless vital for the patient
- No other concurrent investigational treatment
- No other concurrent anticancer agents
Trial locations and contacts
132 sites in 12 countries.
132 sites in 12 countries
United States72 sites
Abington Memorial Hospital
Abington, Pennsylvania
Akron City Hospital - Summa Health System
Akron, Ohio
Lehigh Valley Hospital
Allentown, Pennsylvania
McFarland Clinic
Ames, Iowa, 50010
Saint Joseph Mercy Hospital
Ann Arbor, Michigan
Emory University
Atlanta, Georgia
Summa Barberton Hospital
Barberton, Ohio
UPMC - Heritage Valley Health System - The Medical Center
Beaver, Pennsylvania
Boston Medical Center
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Massachussets General Hospital Cancer Center
Boston, Massachusetts
Medical University of South Carolina
Charleston, South Carolina
Carolinas Medical Center
Charlotte, North Carolina
Northwestern University
Chicago, Illinois
Cleveland Clinic Foundation
Cleveland, Ohio
MetroHealth Medical Center
Cleveland, Ohio
Western Reserve University
Cleveland, Ohio
Ohio State University Medical Center
Columbus, Ohio
Henry Ford Hospital
Detroit, Michigan
Oncology Associates PC
Fort Wayne, Indiana
Parkview Hospital
Fort Wayne, Indiana
University of Florida
Gainesville, Florida
University of Texas Medical Branch
Galveston, Texas
Saint Mary's Hospital
Green Bay, Wisconsin
Saint Vincent Hospital
Green Bay, Wisconsin
Cancer Centers of the Carolinas - Eastside
Greenville, South Carolina
Cancer Centers of the Carolinas - Faris Road
Greenville, South Carolina
Cancer Centers of the Carolinas - Greer Radiation Oncology
Greer, South Carolina
Penn State M.S. Hershey Medical Center
Hershey, Pennsylvania
Md Anderson Cancer Center
Houston, Texas
Methodist Hospital
Houston, Texas
Saint Vincent Oncology Center
Indianapolis, Indiana
Mayo Clinic in Florida
Jacksonville, Florida
West Michigan Cancer Center
Kalamazoo, Michigan
Gundersen Lutheran
La Crosse, Wisconsin
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Cedars-Sinai Medical Center
Los Angeles, California
University Of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin
Loyola University Medical Center
Maywood, Illinois
Southwest General Health Center Ireland Cancer Center
Middleburg Heights, Ohio
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin
Intermountain Medical Center
Murray, Utah
State University of New York Upstate Medical University
New York, New York
Methodist Estabrook Cancer Center
Omaha, Nebraska
UHHS-Chagrin Highlands Medical Center
Orange, Ohio
Florida Hospital
Orlando, Florida
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Arizona Oncology Services Foundation
Phoenix, Arizona
Utah Valley Regional Medical Center
Provo, Utah
Rapid City Regional Hospital
Rapid City, South Dakota
Virginia Commonwealth University
Richmond, Virginia
Highland Hospital
Rochester, New York
University of Rochester - James P. Wilmot Cancer Center
Rochester, New York
Cancer Care Center, Incorporated
Salem, Ohio
LDS Hospital
Salt Lake City, Utah
University Of Utah - Huntsman Cancer Institute
Salt Lake City, Utah
UCSF University of California San Francisco Medical Center-Mount Zion
San Francisco, California
Memorial Health University Medical Center
Savannah, Georgia
Maine Medical Center
Scarborough, Maine
Swedish Cancer Institute
Seattle, Washington
Virginia Mason CCOP
Seattle, Washington
Cancer Centers of the Carolinas - Seneca
Seneca, South Carolina
June E. Nylen Cancer Center
Sioux City, Iowa
Spartanburg Regional Medical Center
Spartanburg, South Carolina
St John's Mercy Medical Center
St Louis, Missouri
Dixie Medical Center Regional Cancer Center
St. George, Utah
Waukesha Memorial Hospital
Waukesha, Wisconsin
Reading Hospital and Medical Center
West Reading, Pennsylvania
UHHS - Westlake Medical Center
Westlake, Ohio
Via Christi Regional Medical Center
Wichita, Kansas
Wesley Medical Center
Wichita, Kansas
Cancer Treatment Center
Wooster, Ohio
United Kingdom12 sites
University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre
Bristol
Addenbrookes Hospital
Cambridge
Cheltenham General Hospital
Cheltenham
Western General Hospital
Edinburgh
Royal Devon And Exeter Hospital
Exeter
St. James'S University Hospital
Leeds
Christie NHS Foundation Trust
Manchester
Clatterbridge Centre for Oncology NHS Trust
Metropolitan Borough of Wirral
Nottingham University Hospitals NHS Trust - City Hospital campus
Nottingham
Derriford Hospital
Plymouth
Weston Park Hospital
Sheffield
Royal Marsden Hospital
Sutton
Australia10 sites
Flinders Medical Centre
Bedford Park
Princess Alexandra Hospital
Brisbane, Queensland, 4102
Austin-Repatriation Medical Centre
Heidelberg
Royal Hobart Hospital
Hobart
St Vincent'S Hospital
Melbourne
Sir Charles Gairdner Hospital
Nedlands
Royal Melbourne Hospital
Parkville, Victoria, 3050
Alfred Hospital
Prahran
Royal North Shore Hospital
St Leonards, New South Wales, 2065
Royal Prince Alfred Hospital
Sydney, New South Wales, 2050
Netherlands7 sites
Academisch Medisch Centrum - Universiteit van Amsterdam
Amsterdam
Vrije Universiteit Medisch Centrum
Amsterdam
University Medical Center Groningen
Groningen
Maastro Clinic - Maastricht Radiation Oncology
Maastricht
Radboud University Nijmegen Medical Centre
Nijmegen
Erasmus MC - Daniel den Hoed Cancer Center
Rotterdam
Medisch Centrum Haaglanden - Westeinde
The Hague
Belgium6 sites
ZNA Middelheim
Antwerp
Cliniques Universitaires St. Luc
Brussels
Universitair Ziekenhuis Brussel
Brussels
Clinique Notre-Dame
Charleroi
Algemeen Ziekenhuis Sint Lucas
Ghent
U.Z. Gasthuisberg
Leuven
France6 sites
Assistance Publique - Hôpitaux de Marseille - C.H.U. De La Timone
Marseille
C.H.U. de Nancy - Hopital St Julien
Nancy
Centre Antoine Lacassagne
Nice
Chu Pitie-Salpetriere AP-HP
Paris
Centre Eugene Marquis
Rennes
Institut Gustave Roussy
Villejuif
Germany6 sites
Klinikum Bamberg
Bamberg
Universitaetsklinikum Bonn
Bonn
Medizinische Hochschule Hannover
Hanover
UniversitaetsKlinikum Heidelberg
Heidelberg
Universitaetskliniken Regensburg
Regensburg
Universitaetsklinikum Tuebingen
Tübingen
Canada5 sites
Tom Baker Cancer Centre
Calgary
London Regional Cancer Center
London
Allan Blair Cancer Centre
Saskatoon
University Health Network - Oci / Princess Margaret Hospital
Toronto
Cancercare Manitoba
Winnipeg
Italy3 sites
Ospedale Bellaria
Bologna
Istituto Scientifico H.S. Raffaele
Milan
Azienda Ospedaliera San Giovanni Battista Di Torino-Universita Di Torino
Torino
Spain2 sites
Hospital Clinic Universitari
Barcelona
ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)
Barcelona
Switzerland2 sites
Hopital Cantonal Universitaire De Geneve
Geneva
Universitaetsspital
Zurich
About this study
Official title: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether giving temozolomide during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma.
PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after radiation therapy to see how well it works compared to radiation therapy alone in treating patients with anaplastic glioma.
Read the detailed description
OBJECTIVES:
Primary
- To assess whether concurrent radiotherapy with daily temozolomide improves overall survival as compared to no daily temozolomide in patients with non-1p/19q deleted anaplastic glioma.
- To assess whether adjuvant temozolomide improves survival as compared to no adjuvant temozolomide in patients with non-1p/19q deleted anaplastic glioma.
Secondary
- To assess whether concurrent and adjuvant temozolomide prolongs progression-free survival and neurological deterioration-free survival in patients with non-1p/19q deleted anaplastic glioma.
- To assess the safety of concurrent and adjuvant temozolomide in patients with non-1p/19q deleted anaplastic glioma, including late effects on cognition.
- To assess the impact of concurrent and adjuvant temozolomide on the quality of life of patients with non-1p/19q deleted anaplastic glioma.
OUTLINE: This is a multicenter study. Patients are stratified according to institution, World Health Organization (WHO) performance status (0 vs > 0), age (≤ 50 vs > 50), presence of 1p LOH only (yes vs no), presence of oligodendroglial elements (yes vs no), and O6-methylguanine-DNA methyltransferase promoter methylation status (methylated vs unmethylated vs indeterminate). Patients are randomized to 1 of 4 treatment arms.
- Arm I: Patients undergo radiotherapy* once daily, 5 days a week, for 6.5 weeks (total of 33 fractions).
- Arm II: Patients undergo radiotherapy* once daily, 5 days a week and receive oral temozolomide once daily for 6.5 weeks (total of 33 fractions of radiotherapy).
- Arm III: Patients undergo radiotherapy* once daily, 5 days a week for 6.5 weeks (total of 33 fractions). Beginning 4 weeks after completion of radiotherapy, patients receive adjuvant oral temozolomide once daily on days 1-5. Treatment with adjuvant temozolomide repeats every 28 days for up to 12 courses.
- Arm IV: Patients undergo radiotherapy* once daily, 5 days a week and receive oral temozolomide once daily for 6.5 weeks (total of 33 fractions of radiotherapy). Beginning 4 weeks after completion of radiotherapy, patients receive adjuvant oral temozolomide once daily on days 1-5. Treatment with adjuvant temozolomide repeats every 28 days for up to 12 courses.
- Patients must begin radiotherapy within 8 days after randomization and within 7 weeks after surgery.
In all arms, treatment continues in the absence of disease progression or unacceptable toxicity.
Patients complete quality-of-life questionnaires, including EORTC core quality of life questionnaire (QLQ-C30) version 3, EORTC brain cancer module (BCM20), and the Mini Mental Status Exam at baseline, 4 weeks after the completion of radiotherapy, and then every 3 months for 5 years.
Tissue samples are collected at baseline for histology review, 1p/19q analysis, methylation status of the O6-methylguanine-DNA methyltransferase promoter, and isocitrate dehydrogenase mutation analysis.
After completion of study treatment, patients are followed every 3 months.
- Conditions
- Brain and Central Nervous System Tumors
- Being tested
- temozolomide, DNA methylation analysis, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment
- Keywords
- adult anaplastic oligodendroglioma, adult anaplastic astrocytoma
- Medical subject headings
- Central Nervous System Neoplasms, Oligodendroglioma, Astrocytoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
temozolomideDrug
Also called Temodar, Temodal
Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
DNA methylation analysisGenetic
O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.
laboratory biomarker analysisOther
Prognostic factor analyses
adjuvant therapyProcedure or surgery
Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
quality-of-life assessmentProcedure or surgery
Quality of Life analysis will also be used to assess neurological deterioration free progression
radiation therapyRadiation
Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
| Study group | Role | What they receive |
|---|---|---|
| Radiotherapy (RT) alone | Active comparator | radiation therapy alone Receives: Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Radiation: radiation therapy |
| RT & Concurrent CT | Active comparator | Radiotherapy and concurrent temozolomide chemotherapy Receives: Drug: temozolomide; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Radiation: radiation therapy |
| RT + Adjuvant CT | Active comparator | Radiotherapy plus adjuvant temozolomide chemotherapy Receives: Drug: temozolomide; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy |
| RT & Concurrent CT + adjuvant CT | Active comparator | Radiotherapy and concurrent chemotherapy plus adjuvant temozolomide chemotherapy Receives: Drug: temozolomide; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival as Measured From the Day of Randomization
The duration of survival is the time interval between randomization and the date of death due to any cause. Patients not reported dead or lost to follow up will be censored at the date of the last follow up examination.
Measured: from date from enrollment till the date of death (time till death is up to 10.9 years after patient enrollment in the study)
Secondary outcomes (3)
Progression-free Survival
Disease progression is defined as radiological or neurological/clinical progression (whichever occurs first); progression free survival (PFS) is the time interval between the date of randomization and the date of disease progression or death whichever occurs first. If neither event has been observed, the patient is censored at the date of the last follow up examination. Radiological progression was defined as increase of contrast enhancing area on MRI or CT scans of more than 25% as measured by two perpendicular diameters compared to the smallest measurements ever recorded for the same lesion by the same technique. The appearance of new lesions with or without contrast enhancement Neurological/clinical progression was defined as:decrease in WHO performance status,deterioration of neurological functions,appearance of signs/symptoms of increased intracranial pressure,and/or start of corticosteroid or increase of corticosteroid dosage by 50% for control of neurological symptoms.
Measured: from randomization till the date of disease progression or death (time till death is up to 10.9 years after patient enrollment in the study)
Quality of Life of the Patient
Quality of life was assessed by the EORTC Quality of Life Questionnaire (QLQ-C30) version 3 and the Brain Cancer Module-20
Measured: from 14 days prior to randomization till five years or death (time till death is up to 10.9 years after patient enrollment in the study)
Neurological Deterioration Free Survival
Neurological deterioration is defined as a decrease in WHO performance status as follows:
decrease in WHO performance status
- for patients with baseline WHO performance status 0: deterioration to WHO performance status 2 or worse for which no other explanation is present, and which is maintained for at least three months
- for patients with baseline WHO performance status 1 or 2: deterioration to WHO performance status 3 or worse for which no other explanation is present and which is maintained for at least three months
The date of neurological deterioration will be the first date the persistent decrease in performance status was diagnosed. Neurological deterioration free progression is the time interval between the date of randomization and the date of neurological deterioration or death whichever occurs first. If neither event has been observed, the patient is censored at the date of the last follow up examination
Measured: within 2 weeks of randomization; during radiotherapy at week 4 and 6; 4 weeks after the end of radiotherapy; Six monthly after the end of radiotherapy; Prior to each cycle of adjuvant therapy; Every six months after the documentation of first progression.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Feb 2008 (estimated)
- Study startDec 2007
- Primary completion5 Sep 2018
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Brain and Central Nervous System TumorsStudies of the same condition, open and under way.
- More trials run by European Organisation for Research and Treatment of Cancer - EORTCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 751 participants (actual)
Sponsor and investigators
- Sponsor type
- Research network
- Collaborators
- NCIC Clinical Trials Group, Radiation Therapy Oncology Group, Medical Research Council, Merck Sharp & Dohme LLC
- Responsible party
- Sponsor
- Investigators
- Wolfgang Wick, Study chair, UNIVERSITATSKLINIKUM HEIDELBERGWarren P. Mason, MD, Study chair, Princess Margaret Hospital, CanadaMichael A. Vogelbaum, MD, PhD, Study chair, The Cleveland ClinicS. Erridge, Study chair, Medical Research CouncilAnna Nowak, MD, Study chair, Sir Charles Gairdner Hospital - Nedlands
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00626990
- Sponsor's protocol ID
- EORTC-26053-22054
- Other IDs
- NCIC CTG CEC.1, RTOG-0834, 2006-001533-17, P04839, MRC BR14
- Acronym
- CATNON
- Status last verified
- Aug 2023
- First submitted
- 28 Feb 2008
- Last updated
- 11 Sep 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
van den Bent MJ, Ghisai SA, Wick W, Sanson M, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Tabouret E, Gill S, Griffin M, Taal W, Ruda R, Weller M, McBain C, Reijneveld JC, Enting RH, Tran S, Lesimple T, Kocher M, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Hoogstrate Y, Nuyens S, Golfinopoulos V, Tesileanu CMS, Gorlia T, French P, Baumert BG. Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial. Lancet Oncol. 2026 Jan;27(1):45-56. doi: 10.1016/S1470-2045(25)00614-X.
PubMed 41449147Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Ruda R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clin Cancer Res. 2022 Jun 13;28(12):2527-2535. doi: 10.1158/1078-0432.CCR-21-4283.
PubMed 35275197van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14.
PubMed 34000245van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8.
PubMed 28801186